HomeCompareOCEAW vs CHD

OCEAW vs CHD: Dividend Comparison 2026

OCEAW yields 6711.41% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OCEAW wins by $1097629163471472.38M in total portfolio value
10 years
OCEAW
OCEAW
● Live price
6711.41%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1097629163471472.38M
Annual income
$1,066,373,173,675,476,400,000.00
Full OCEAW calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — OCEAW vs CHD

📍 OCEAW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOCEAWCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OCEAW + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OCEAW pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OCEAW
Annual income on $10K today (after 15% tax)
$570,469.80/yr
After 10yr DRIP, annual income (after tax)
$906,417,197,624,154,900,000.00/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, OCEAW beats the other by $906,417,197,624,154,900,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OCEAW + CHD for your $10,000?

OCEAW: 50%CHD: 50%
100% CHD50/50100% OCEAW
Portfolio after 10yr
$548814581735736.19M
Annual income
$533,186,586,837,738,200,000.00/yr
Blended yield
97.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

OCEAW
No analyst data
Altman Z
-268.6
Piotroski
1/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OCEAW buys
0
CHD buys
0
No recent congressional trades found for OCEAW or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOCEAWCHD
Forward yield6711.41%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$1097629163471472.38M$26.4K
Annual income after 10y$1,066,373,173,675,476,400,000.00$1,292.51
Total dividends collected$1095532211199846.75M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: OCEAW vs CHD ($10,000, DRIP)

YearOCEAW PortfolioOCEAW Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$681,841$671,140.94$10,856$156.32+$671.0KOCEAW
2$43,496,987$42,767,417.65$11,811$195.24+$43.49MOCEAW
3$2,596,337,307$2,549,795,530.67$12,883$244.38+$2596.32MOCEAW
4$145,018,660,220$142,240,579,301.68$14,091$306.64+$145018.65MOCEAW
5$7,580,273,425,477$7,425,103,459,041.20$15,463$385.88+$7580273.41MOCEAW
6$370,837,750,892,272$362,726,858,327,011.50$17,033$487.17+$370837750.88MOCEAW
7$16,981,014,621,956,098$16,584,218,228,501,366.00$18,843$617.36+$16981014621.94MOCEAW
8$727,896,026,099,293,400$709,726,340,453,800,300.00$20,947$785.72+$727896026099.27MOCEAW
9$29,211,205,416,818,827,000$28,432,356,668,892,580,000.00$23,419$1,004.91+$29211205416818.80MOCEAW
10$1,097,629,163,471,472,400,000$1,066,373,173,675,476,400,000.00$26,350$1,292.51+$1097629163471472.38MOCEAW

OCEAW vs CHD: Complete Analysis 2026

OCEAWStock

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.

Full OCEAW Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this OCEAW vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OCEAW vs SCHDOCEAW vs JEPIOCEAW vs OOCEAW vs KOOCEAW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.